Molecular Recognition of the Colchicine Binding Site as a Design Paradigm for the Discovery and Development of Vascular Disrupting Agents

Vascular-Targeted Therapies in Oncology

Volumn , Issue , 2006, Pages 95-121

  Pinney, Kevin G ^a  

^a BAYLOR UNIVERSITY   (United States)

Author keywords

Colchicine binding site on tubulin; Molecular recognition of colchicine binding site; Small molecule inhibitor of tubulin assembly; Small molecule VDAs in phase I, Ib and II clinical trials; Successful molecular architecture; Tubulin microtubule protein system drug intervention target; Vascular disruption; Vascular disruption therapy

Indexed keywords

EID: 84890590630     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470035439.ch6     Document Type: Chapter

References (130)

1. Baguley, B.C. (2003). Antivascular therapy of cancer: DMXAA. Lancelot Oncol 4, 141-148.
2. Baguley, B.C., Holdaway, K.M., Thomsen, L.L., Zhuang, Li and Zwi, L.J. (1991). Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicines: evidence for a vascular mechanism. Eur J Cancer 27, 482-487.
3. Baguley, B.C. and Wilson, W.R. (2002). Potential of DMXAA combination therapy for solid tumors. Exp Rev Anticancer Ther 2, 593-603.
4. Bai, R., Pei, X.F., Boye, O., Getahun, Z., Grover, S., Bekisz, J., Nguyen, N.Y., Brossi, A. and Hamel, E. (1996). Identification of cysteine 354 of beta-tubulin as part of the binding site for the a ring of colchicines. J Biol Chem 271, 12639-12645.
5. Bibby, M.C. (2002). Combretastatin anticancer drugs. Drugs Future 27, 475-480.
6. Blakey, D.C., Ashton, S.E., Westwood, F.R., Walker, M. and Ryan, A.J. (2002). ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54, 1497-1502.
7. Boyland, E. and Boyland, M.E. (1937). Studies in tissue metabolism. IX. The action of colchicine and B typhosus extract. Biochem J 31, 454-460.
8. Chaplin, D.J. and Dougherty, G.J. (1999). Tumour vasculature as a target for cancer therapy. Br J Cancer 80, 57-64.
9. Chaplin, D.J., Edvardsen, K., Pinney, K.G., Prezioso, J.A. and Wood, M. (2004). Preparation of quinone and catechol derivatives for the treatment of cancers and other vascular proliferative disorders. PCT Int Application WO 2004078126 A2.
10. Chaplin, D.J., Garner, C.M., Kane, R.R., Pinney, K.G, and Prezioso, J.A. (2003) Preparation of stilbenes as vascular targeting agents (VTAs) for treatment of solid tumors and retinal neovascularization. PCT Int Application WO2003035008 A2.
11. Chaplin, D.J., Garner, C.M. III, Kane, R.R., Pinney, K.G. and Prezioso, J.A. (2003) Functionalized stilbene derivatives as improved vascular targeting agents. US Patent Application 20030149003 A1.
12. Chaplin, D.J. and Hill, S.A. (2002). The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54, 1491-1496.
13. Chaplin, D.J., Pettit, G.R. and Hill, S.A. (1999). Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19, 189-196.
14. Chaplin, D.J., Pettit, G.R., Parkins, C.S. and Hill, S.A. (1996). Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 27, S86-S88.
15. Chavan, A.J., Richardson, S.K., Kim, H., Haley, B.E. and Watt, D.S. (1993). Forskolin photoaffinity probes for the evaluation of tubulin binding sites. Bioconj Chem 4, 268-274.
16. Chen, Z., Mocharla, V.P., Farmer, J.M., Pettit, G.R., Hamel, E. and Pinney, K.G. (2000). Preparation of new anti-tubulin ligands through a dual-mode, addition-elimination reaction to a bromo-substituted a,b-unsaturated sulfoxide. J Org Chem 65, 8811-8815.
17. Cirla, A. and Mann, J. (2003). Combretastatins: from natural products to drug discovery. Nat Prod Rep 20, 558-564.
18. Cushman, M., Nagarathnam, D., Gopal, D., Chakraborti, A.K., Lin, C.M. and Hamel, E. (1991). Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34, 2579-2588.
19. Desbene, S. and Giorgi-Renault, S. (2002). Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues. Curr Medicinal Chem: Anti-Cancer Agents 2, 71-90.
20. Downing, K.H. (2000). Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Biol 16, 89-111.
21. Duax, W.L., Griffin, J.F., Weeks, C.M. and Korach, K.S. (1985). Molecular conformation, receptor binding, and hormone action of natural and synthetic estrogens and antiestrogens. Environ Health Perspect 61, 111-121.
22. Edvardsen, K. and Pinney, K.G. (2005). Unpublished results, University of Lund, Sweden, and Baylor University, Waco, TX.
23. Eikesdal, H.P., Schem, B.C., Mella, O. and Dahl, O. (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 46, 645-652.
24. Floyd, L.J., Barnes, L.D. and Williams, R.F. (1989). Photoaffinity labeling of tubulin with (2-nitro-4-azidophenyl)deacetylcolchicine: direct evidence for two colchicine binding sites. Biochemistry 28, 8515-8525.
25. Flygare, J.A., Medina, J.C., Shan, B., Clark, D.L. and Rosen, T.J. (2000). Pentafluorobenzenesulfonamides and analogs. US Patent 6121304.
26. Flynn, B.L., Flynn, G.P., Hamel, E. and Jung, M.K. (2001). The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg Med Chem Lett 11, 2341-2343.
27. Flynn, B.L. and Hamel, E. (2002) Synthesis of indoles, benzofurans, and related compounds as potential tubulin binding agents. PCT Int Application WO2002060872 A1.
28. Flynn, B.L., Hamel, E. and Jung, M.K. (2002). One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J Med Chem 45, 2670-2673.
29. Flynn, B.L., Verdier-Pinard, P. and Hamel, E. (2001). A novel palladium-mediated coupling approach to 2,3-disubstituted benzo[b]thiophenes and its application to the synthesis of tubulin binding agents. Org Lett 3, 651-654.
30. Galbraith, S.M., Chaplin, D.J., Lee, F., Stratford, M.R.L., Locke, R.J., Vojnovic, B. and Tozer, G.M. (2001). Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 21, 93-102.
31. Gastpar, R., Goldbrunner, M., Marko, D. and Von Angerer, E. (1998). Methoxysubstituted 3-formyl-2-phenylindoles inhibit tubulin polymerization, J Med Chem 41, 4965-4972.
32. Gaya, A.M. and Rustin, G.J.S. (2005). Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol 17, 277-290.
33. Ghatak, A., Dorsey, J.M., Garner, C.M. and Pinney, K.G. (2003). Synthesis of methoxy and hydroxy containing tetralones: versatile intermediates for the preparation of biologically relevant molecules. Tetrahedron Lett 44, 4145-4148.
34. Goldbrunner, M., Loidl, G., Polossek, T., Mannschreck, A. and Von Angerer, E. (1997). Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-a]isoquinoline derivatives. J Med Chem 40, 3524-3533.
35. Grosios, K., Loadman, P.M., Swaine, D.J., Pettit, G.R. and Bibby, M.C. (2000). Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20, 229-233.
36. Hadimani, M., Kessler, R.J., Kautz, J.A., Ghatak, A., Shirali, A., O'Dell. H., Garner, C.M. and Pinney, K.G. (2002). 2-(3-tert-Butyldimethylsiloxy-4-methoxyphenyl)-6 methoxy-3-(3,4,5-trimethoxybenzoyl)indole. Acta Cryst C: Crystal Struct Comm C58, 330-332.
37. Hadimani, M.B. (December 2004). Studies Toward the Discovery of New Classes of Privileged Molecules as Colchicine-Site Binding Ligands for Tubulin: Structure-Based Design, Synthesis, and Bioactivity of Small Ligands Targeted at Tumor Vasculature, Ph.D. Dissertation, Baylor University.
38. Hahn, K.M., Hastie, S.B. and Sundberg, R.J. (1992). Synthesis and evaluation of 2-diazo-3,3,3-trifluopropanoyl derivatives of colchicine and podophyllotoxin as photoaffinity labels: reactivity, photochemistry, and tubulin binding. Photochem Photobiol 55, 17-27.
39. Hall, J. (2005). Baylor University, (personal communication).
40. Hamel, E. (1996). Antimitotic natural products and their interactions with tubulin. Med Res Rev 16, 207-231.
41. Hamel, E. and Pinney, K.G. 2005. Unpublished results, National Institutes of Health, National Cancer Institute-Frederick, MD, and Baylor University, Waco, TX.
42. Hartung, E.F. (1961). Colchicine and its analogs in gout: a brief review. Arthritis Rheumatism 4, 18-26.
43. Hill, S.A., Tozer, G.M., Pettit, G.R. and Chaplin, D.J. (2002). Preclinical evaluation of the antitumour activity of the novel vascular targeting agent OXi 4503. Anticancer Res 22, 1453-1458.
44. Holwell, S.E., Cooper, P.A., Grosios, K., Lippert, J.W. III, Pettit, G.R., Shnyder, S.D. and Bibby, M.C. (2002). Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res 22, 3933-3940.
45. Hori, K. and Saito, S. (2003). Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 89, 1334-1344.
46. Horsman, M.R. and Murata, R. (2002). Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 54, 1518-1523.
47. Horsman, M.R., Murata, R., Breidahl, T., Nielsen, F.U., Maxwell, R.J., Stodkiled-Jorgensen, H. and Overgaard, J. (2000). Combretastatins: novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 476, 311-323.
48. Hua, J., Sheng, Y., Pinney, K.G., Garner, C.M., Kane, R.R., Prezioso, J.A., Pettit, G.R., Chaplin, D.J. and Edvardsen, K. (2003). Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23, 1433-1440.
49. Jelinek, C.J. (December 2004). Discovery and Development of Dihydronaphthalene-Based Vascular Targeting Agents and Combretastatin-Related Analogs, Thesis, Baylor University.
50. Jordan, M.A. and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature Rev 4, 253-265.
51. Jordon, A., Hadfield, J.A., Lawrence, N.J. and McGown, A.T. (1998). Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18, 259-296.
52. Kanthou, C. and Tozer, G.M. (2002). The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060-2069.
53. King, M.V., DeVries, J.L. and Pepinsky, R. (1952). X-ray diffraction determination of the chemical structure of colchicine. Acta Crystallosr 5, 437-440.
54. Kingston, D.G.I., Samaranayake, G. and Ivey, C.A. (1990). The chemistry of taxol, a clinically useful anticancer agent. J Nat Prod 53, 1-12.
55. Landuyt, W., Ahmed, B., Nuyts, S., Theys, J., Op de Beeck, M., Rijnders, A., Anne, J., Van Oosterom, A., Van Den Bogaert, W. and Lambin, P. (2001). In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49, 443-450.
56. Li, L., Rojiani, A. and Siemann, D.W. (1998). Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42, 899-903.
57. Li, Q. and Sham, H.L. (2002). Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. Exp Opin Ther Pat 12, 1663-1702.
58. Li, Q., Woods, K.W., Claiborne, A., Gwaltney, S.L. II, Barr, K.J., Liu, G., Gehrke, L., Credo, R.B., Hui, Y.H., Lee, J., Warner, R.B., Kovar, P., Nukkala, M.A., Zielinski, N.A., Tahir, S.K., Fitzgerald, M., Kim, K.H., Marsh, K., Frost, D., Ng, S.C., Rosenberg, S. and Sham, H.L. (2002). Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg Med Chem Lett 12, 465-469.
59. Lin, C.M., Ho, H.H., Pettit, G.R. and Hamel, E. (1989). Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28, 6984-6991.
60. Lin, C.M., Singh, S.B., Chu, P.S., Dempcy, R.O., Schmidt, J.M., Pettit, G.R. and Hamel, E. (1988). Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol 34, 200-208.
61. Lowe, J., Li, H., Downing, K.H., Nogales, E. (2001). Refined structure of ab-tubulin at 3.5 Å resolution. J Mol Biol 313, 1045-1057.
62. Ludford, R.J. (1948). Factors determining the action of colchicine on tumor growth. Br J Cancer 2, 75-86.
63. McGown, A.T. and Fox, B.W. (1989). Structural and biochemical comparison of the antimitotic agents colchicine, combretastatin A4 and amphethinile. Anti-Cancer Drug Des 3, 249-254.
64. Medina, J.C., Clark, D.L., Flygare, J.A., Rosen, T.J. and Shan, B. (1999). Pentafluorobenzenesulfonamides and analogs. US Patent 5880151.
65. Micheletti, G., Poli, M., Borsotti, P., Martinelli, M., Imberti, B., Taraboletti, G. and Giavazzi, R. (2003). Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 63, 1534-1537.
66. Nakada, M., Kobayashi, S., Shibasaki, M., Iwasaki, S. and Ohno, M. (1993). The first total synthesis of the antitumor macrolide, rhizoxin. Tetrahedron Lett 34, 1039-1042.
67. Nelkin, B.D. and Ball, D.W. (2001). Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8, 157-160.
68. Nicolaou, K.C., Winssinger, N., Pastor, J., Ninkovic, S., Sarabia, F., He, Y., Vourloumis, D., Yang, Z., Li, T., Giannakakou, P. and Hamel, E. (1997). Synthesis of epothilones A and B in solid and solution phase. Nature 387, 268-272.
69. Nogales, E. (2000). Structural insights into microtubule function. Annu Rev Biochem 69, 277-302.
70. Nogales, E., Wolf, S.G. and Downing, K.H. (1998). Structure of the a,b tubulin dimer by electron crystallography. Nature 391, 199-203.
71. Ohsumi, K., Hatanaka, T., Nakagawa, R., Fukuda, Y., Morinaga, Y., Suga, Y., Nihei, Y., Ohishi, K., Akiyama, Y. and Tsuiji, T. (1999). Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anti-Cancer Drug Des 14, 539-548.
72. Ohsumi, K., Nakagawa, R., Fukuda, Y., Hatanaka, T., Morinaga, Y., Nihei, Y., Ohishi, K., Suga, Y., Akiyama, Y. and Tsuji, T. (1998). Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J Med Chem 41, 3022-3032.
73. Olszewski, J.D., Marshalla, M., Sabat, M. and Sundberg, R.J. (1994). Potential photoaffi-nity labels for tubulin. Synthesis and evaluation of diazocyclohexadienone and azide analogs of colchicine, combretastatin, and 3,4,5-trimethoxybiphenyl. J Org Chem 59, 4285-4296.
74. Owellen, R.J., Hartke, C.A., Dickerson, R.M. and Hains, F.O. (1976). Inhibition of tubulinmicrotubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36, 1499-1502.
75. Pedley, R.B., Hill, S.A., Boxer, G.M., Flynn, A.A., Boden, R., Watson, R., Dearling, J., Chaplin, D.J. and Begent, R.H.J. (2001). Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61, 4716-4722.
76. Pettit, G.R., Cragg, G.M., Herald, D.L., Schmidt, J.M. and Lohavanijaya, P. (1982). Isolation and structure of combretastatin. Can J Chem 60, 1374-1376.
77. Pettit, G.R., Cragg, G.M. and Singh, S.B. (1987). Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 50, 386-391.
78. Pettit, G.R., Kamano, Y., Herald, C.L., Tuinman, A.A., Boettner, F.E., Kizu, H., Schmidt, J.M., Baczynskyj, L., Tomer, K.B. and Bontems, R.J. (1987). The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 109, 6883-6885.
79. Pettit, G.R. and Lippert, J.W. (2000). Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anti-Cancer Drug Des 15, 203-216.
80. Pettit, G.R. and Pinney, K.G. (2005). Unpublished results. Arizona State University, Tempe, AZ, and Baylor University, Waco, TX.
81. Pettit, G.R. and Singh, S.B. (1987). Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can J Chem 65, 2390-2396.
82. Pettit, G.R. and Singh, S.B. (1996). Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated 'combretastatins'. US Patent 5569786.
83. Pettit, G.R., Singh, S.B., Boyd, M.R., Hamel, E., Pettit, R.K., Schmidt, J.M. and Hogan, F. (1995). Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J Med Chem 38, 1666-1672.
84. Pettit, G.R., Singh, S.B. and Niven, M.L. (1988). Isolation and structure of combretastatin D-1: a cell growth inhibitory macrocyclic lactone from Combretum caffrum. J Am Chem Soc 110, 8539-8540.
85. Pettit, G.R., Singh, S.B., Niven, M.L., Hamel, E. and Schmidt, J.M. (1987c). Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50, 119-131.
86. Pettit, G.R., Srirangam, J.K., Barkoczy, J., Williams, M.D., Boyd, M.R., Hamel, E.,Pettit, R.K., Hogan, F., Bai, R., Chapuis, J.C., McAllister, S.C. and Schmidt, J.M. (1998). Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des 13, 243-277.
87. Pettit, G.R., Temple, C. Jr., Narayanan, V.L., Varma, R., Simpson, M.J., Boyd, M.R., Rener, G.A. and Bansal, N. (1995). Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des 10, 299-309.
88. Pettit, G.R., Toki, B., Herald, D.L., Verdier-Pinard, P., Boyd, M.R., Hamel, E. and Pettit, R.K. (1998). Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J Med Chem 41, 1688-1695.
89. Pinney, K.G., Bounds, A.D., Dingeman, K.M., Mocharla, V.P., Pettit, G.R., Bai, R. and Hamel, E. (1999). A new anti-tubulin agent containing the benzo[b]thiophene ring system. Bioorg Med Chem Lett 9, 1081-1086.
90. Pinney, K.G., Edvardsen, K., Chaplin, D.J., Hadimani, M.B., Kessler, R.J., Jelinek, C. and Arthesary, P. (2004) Molecular recognition of the colchicine binding site as a design paradigm for the discovery and development of new vascular targeting (disrupting) agents. Second International Vascular Targeting Conference, Miami Beach, FL, 2004.
91. Pinney, K.G., Jelinek, C.J., Edvardsen, K., Chaplin, D.J. and Pettit, G.R. (2005) The discovery and development of the combretastatins. In Antitumor Agents from Natural Products, D. Kingston, D. Newman and G. Cragg (eds). CRC Press, Boca Raton, FL, Chapter 3, pp. 23-46.
92. Pinney, K.G., Mejia, P., Mocharla, V.P., Shirali, A. and Pettit, G.R. (2000) Anti-mitotic agents which inhibit tubulin polymerization. US Patent 6162930.
93. Pinney, K.G., Mejia, M.P., Villalobos, V.M., Rosenquist, B.E., Pettit, G.R., Verdier-Pinard, P. and Hamel, E. (2000). Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg Med Chem 8, 2417-2425.
94. Pinney, K.G., Mocharla, V.P., Chen, Z., Garner, C.M., Ghatak, A. and Dorsey, J.M. (2003). Tubulin binding ligands and corresponding prodrug constructs. US Patent 6593374.
95. Pinney, K.G., Mocharla, V.P., Chen, Z., Garner, C.M., Ghatak, A., Hadimani, M., Kessler, J. and Dorsey, J.M. (2001) Preparation of trimethoxyphenyl-containing tubulin binding ligands and corresponding prodrug constructs as inhibitors of tubulin polymerization and antimitotic agents. PCT Int Application WO2001068654.
96. Pinney, K.G., Mocharla, V.P., Chen, Z., Garner, C.M., Hadimani, M., Kessler, R., Dorsey, J.M., Edvardsen, K., Chaplin, D.J., Prezioso, J., Ghatak, A. and Ghatak, U. (2004) Tubulin binding ligands and corresponding prodrug constructs. US Patent Application 2004044059 A1.
97. Pinney, K.G., Mocharla, V.P., Chen, Z., Garner, C.M., Hadimani, M., Kessler, R., Dorsey, J.M., Edvardsen, K., Chaplin, D.J., Prezioso, J., Ghatak, A. and Ghatak, U. (2004c). Tubulin binding ligands and corresponding prodrug constructs. US Patent Application 20040043969 A1.
98. Pinney, K.G., Pettit, G.R., Mocharla, V.P., Mejia, M.P. and Shirali, A. (2000c). Description of anti-mitotic agents which inhibit tubulin polymerization. US Patent 6350777.
99. Pinney, K.G., Wang, F. and Del Pilar Mejia, M. (2001) Preparation of indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents. PCT Int Application WO2001019794 A2.
100. Pinney, K.G., Wang, F. and Hadimani, M. (2005) Indole-containing and combretastatinrelated anti-mitotic and anti-tubulin polymerization agents. US Patent 6849656.
101. Rao, S., Horwitz, S.B. and Ringel, I. (1992). Direct photoaffinity labeling of tubulin with taxol. J Natl Cancer Inst 84, 785-788.
102. Ravelli, R.B.G., Gigant, B., Curmi, P.A., Jourdain, I., Lachkar, S., Sobel, A., Knossow, M. (2004). Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428, 198-202.
103. Safa, A.R., Hamel, E., Felsted, R.L. (1987). Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine. Biochemistry 26, 97-102.
104. Sawada, T., Hashimoto, Y., Li, Y., Kobayashi, H. and Iwasaki, S. (1991). Fluorescent and photoaffinity labeling derivatives of rhizoxin. Biochem Biophys Res Comm 178, 558-562.
105. Sawada, T., Kato, Y., Kobayashi, H., Hashimoto, Y., Watanabe, T., Sugiyama, Y. and Iwasaki, S. (1993). A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. Bioconj Chem 4, 284-289.
106. Sawada, T., Kobayashi, H., Hashimoto, Y. and Iwasaki, S. (1993) Identification of the fragment photoaffinity-labeled with azidodansyl-rhizoxin as Met-363-Lys-379 on betatubulin. Biochem Pharmacol 45, 1387-1394.
107. Sheng, Y., Hua, J., Pinney, K.G., Garner, C.M., Kane, R.R., Prezioso, J.A., Chaplin, D.J. and Edvardsen, K. (2004). Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 111, 604-610.
108. Shirali, A.R. (2002). Inhibitors of Tubulin Assembly: Designed Ligands Featuring Benzo[b]thiophene, Dihydronaphthalene and Aroylchromene Molecular Core Structures, Ph.D. Dissertation, Baylor University.
109. Shnyder, S.D., Cooper, P.A., Pettit, G.R., Lippert, J.W. III, and Bibby, M.C. (2003). Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 23, 1619-1623.
110. Siemann, D.W. (2002). Vascular targeting agents: an introduction. Int J Radiat Oncol Biol Phys 54, 1472.
111. Siemann, D.W., Bibby, M.C., Dark, G.G., Dicker, A.P., Eskens, F.A.L.M., Horsman, M.R., Marme, D. and LoRusso, P.M. (2005). Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11, 416-420.
112. Siemann, D.W., Chaplin, D.J. and Horsman, M.R. (2004). Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491-2499.
113. Siemann, D.W., Mercer, E., Lepler, S. and Rojiani, A.M. (2002). Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99, 1-6.
114. Siemann, D.W. and Rojiani, A.M. (2002). Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53, 164-171.
115. Siemann, D.W. and Rojiani, A.M. (2002c). Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54, 1512-1517.
116. Singh, S.B. and Pettit, G.R. (1989). Isolation, structure, and synthesis of combretastatin C-1. J Org Chem 54, 4105-4114.
117. Staretz, M.E. and Hastie, S.B. (1993). Synthesis, photochemical reactions, and tubulin binding of novel photoaffinity labeling derivatives of colchicines. J Org Chem 58, 1589-1592.
118. Szala, S. (2004). Two-domain vascular disruptive agents in cancer therapy. Curr Cancer Drug Targets 4, 501-509.
119. Tahir, S.K., Nukkala, M.A., Mozny, N.A.Z., Credo, R.B., Warner, R.B., Li, Q., Woods, K.W., Claiborne, A., Gwaltney, S.L. II, Frost, D.J., Sham, H.L., Rosenberg, S.H. and Ng, S.C. (2003). Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol Cancer Ther 2, 227-233.
120. Thorpe, P.E. (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427.
121. Thorpe, P.E., Chaplin, D.J. and Blakey, D.C. (2003). The first international conference on vascular targeting: meeting overview. Cancer Res 63, 1144-1147.
122. Tozer, G.M., Kanthou, C., Parkins, C.S. and Hill, S.A. (2002). The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83, 21-38.
123. Tozer, G.M., Prise, V.E., Wilson, J., Cemazar, M., Shan, S., Dewhirst, M.W., Barber, P.R., Vojnovic, B. and Chaplin, D.J. (2001). Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61, 6413-6422.
124. Wang, L., Woods, K.W., Li, Q., Barr, K.J., McCroskey, R.W., Hannick, S.M., Gherke, L., Credo, R.B., Hui, Y.H., Marsh, K., Warner, R., Lee, J.Y., Zielinski-Mozng, N., Frost, D., Rosenberg, S.H. and Sham, H.L. (2002). Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 45, 1697-1711.
125. Wehbe, H. (2005). Towards Enhanced Chemotherapy: Studies on Drug Design, Synergy, and Drug Target Expression and Resistance with the Combretastatins and Other Chemotherapeutics, Ph.D. Dissertation, Baylor University.
126. Wildiers, H., Ahmed, B., Guetens, G., De Boeck, G., De Bruijn, E.A., Landuyt, W. and Van Oosterom, A.T. (2004). Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 40, 284-290.
127. Williams, R.F., Mumford, C.L., Williams, G.A., Floyd, L.J., Aivaliotis, M.J., Martinez, R.A., Robinson, A.K. and Barnes, L.D. (1985). A photoaffinity derivative of colchicine: 6¢-(4¢-azido-2¢-nitrophenylamino)hexanoyldeacetylcolchicine. Photolabeling and location of the colchicine binding site on the alpha-subunit of tubulin. J Biol Chem 260, 13794-13802.
128. Wolff, J., Knipling, L., Cahnman, H.J. and Palumbo, G. (1991). Direct photoaffinity labeling of tubulin with colchicines. Proc Natl Acad Sci USA 88, 2820-2824.
129. Young, S. and Chaplin, D.J. (2004). Combretastatin A4 phosphate: background and current clinical status. Exp Opin Invest Drugs 13, 1171-1182.
130. Zhou, S., Kestell, P., Baguley, B.C. and Paxton, J.W. (2002). 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Investigational New Drugs 20, 281-295.